CELS: Composite Endpoint for Liver Surgery Validation in Intrahepatic Cholangiocarcinoma

Constantin Scholz published a dataset on 2026-05-15 for validating the Composite Endpoint for Liver Surgery (CELS) in predicting surgery-related mortality. It includes data from 227 patients who underwent liver resection for intrahepatic cholangiocarcinoma, with 90-day mortality rates and CELS performance metrics. The dataset is available under a CC-BY-4.0 license on figshare.

Use Cases

• Validate predictive models for surgery-related mortality based on the CELS endpoint.
• Analyze associations between surgical outcomes and patient cohorts based on 90-day mortality and length of hospital stay.
• Benchmark model performance using reported sensitivity (81.8%), specificity (66.3%), and AUC (0.74) metrics.

Strengths

• Includes data from 227 patients, providing a specific cohort size.
• Reports key performance metrics for the CELS endpoint, including sensitivity, specificity, and AUC.
• Focuses on a distinct validation cohort for intrahepatic cholangiocarcinoma, addressing a noted limitation in external validation.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a single DOCX file (853.4 KB), which suggests limited scope and may require data extraction.

Provenance

Source

figshare

Collection Method

Data likely collected from a clinical study of patients undergoing liver resection for intrahepatic cholangiocarcinoma.

Freshness

Last updated 2026-05-15 04:24:03; freshness should be verified.